JP2006502231A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502231A5
JP2006502231A5 JP2004546786A JP2004546786A JP2006502231A5 JP 2006502231 A5 JP2006502231 A5 JP 2006502231A5 JP 2004546786 A JP2004546786 A JP 2004546786A JP 2004546786 A JP2004546786 A JP 2004546786A JP 2006502231 A5 JP2006502231 A5 JP 2006502231A5
Authority
JP
Japan
Prior art keywords
hemoglobin
use according
solution
polymerized
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004546786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031377 external-priority patent/WO2004037279A1/en
Publication of JP2006502231A publication Critical patent/JP2006502231A/ja
Publication of JP2006502231A5 publication Critical patent/JP2006502231A5/ja
Pending legal-status Critical Current

Links

JP2004546786A 2002-10-03 2003-10-03 大量失血を被っている患者の処置方法 Pending JP2006502231A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41593502P 2002-10-03 2002-10-03
PCT/US2003/031377 WO2004037279A1 (en) 2002-10-03 2003-10-03 Method for treating patients with massive blood loss

Publications (2)

Publication Number Publication Date
JP2006502231A JP2006502231A (ja) 2006-01-19
JP2006502231A5 true JP2006502231A5 (https=) 2006-10-05

Family

ID=32176456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004546786A Pending JP2006502231A (ja) 2002-10-03 2003-10-03 大量失血を被っている患者の処置方法

Country Status (11)

Country Link
US (1) US7291592B2 (https=)
EP (1) EP1553968A4 (https=)
JP (1) JP2006502231A (https=)
CN (1) CN1703235A (https=)
AU (1) AU2003272827B2 (https=)
CA (1) CA2499459A1 (https=)
MX (1) MXPA05003340A (https=)
NO (1) NO20051390L (https=)
RU (1) RU2325924C2 (https=)
WO (1) WO2004037279A1 (https=)
ZA (1) ZA200502307B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049707A1 (en) * 2003-08-29 2005-03-03 Ferree Bret A. Cemented artificial disc replacements
EP1471821B1 (en) * 2002-01-15 2013-06-26 Board Of Regents, The University Of Texas System Compositions to reduce scattering of light during therapeutic and diagnostic imaging procedures
US20070196810A1 (en) * 2006-01-24 2007-08-23 Northfield Laboratories Inc. Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
WO2008009634A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
RU2361608C1 (ru) * 2008-03-18 2009-07-20 Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Медбиофарм" Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты)
RU2452519C1 (ru) * 2011-03-25 2012-06-10 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ компенсации глобулярного объема крови и иммуномодулирующего воздействия при трансплантации
CA3070172A1 (en) 2017-07-18 2019-01-24 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194590A (en) * 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5464814A (en) * 1986-06-20 1995-11-07 Northfield Laboratories, Inc. Acellular red blood cell substitute
US4826811A (en) * 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5955581A (en) * 1986-11-10 1999-09-21 Biopure Corporation Method for producing a stable polymerized hemoglobin blood-substitute
US5854209A (en) 1995-03-23 1998-12-29 Biopure Corporation Method for oxygenating tissue having reduced red blood cell flow
US5084558A (en) * 1987-10-13 1992-01-28 Biopure Corporation Extra pure semi-synthetic blood substitute
US5691452A (en) * 1995-03-23 1997-11-25 Biopure Corporation Method for preserving a hemoglobin blood substitute
NZ305258A (en) * 1995-03-23 2000-10-27 Biopure Corp Stable polymerised haemoglobin blood-substitute to treat or prevent hypoxia resulting from blood loss
US6288027B1 (en) * 1995-03-23 2001-09-11 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
US5895810A (en) * 1995-03-23 1999-04-20 Biopure Corporation Stable polymerized hemoglobin and use thereof
US6271351B1 (en) * 1995-03-23 2001-08-07 Biopure Corporation Method for preserving a hemoglobin blood substitute
US20020065211A1 (en) * 1995-03-23 2002-05-30 Biopure Corporation Increasing function of organs having reduced red blood cell flow
US6150507A (en) * 1995-03-23 2000-11-21 Biopure Corporation Method for producing a purified hemoglobin product
US5691453A (en) * 1995-06-07 1997-11-25 Biopure Corporation Separation of polymerized hemoglobin from unpolymerized hemoglobin on hydroxyapatite using HPLC
RU2203087C2 (ru) * 1996-03-28 2003-04-27 Нортфилд Лэборэтериз, Инк. Способ и устройство для получения бесклеточного заменителя эритроцитов
US5890852A (en) * 1998-03-17 1999-04-06 Emerson Electric Company Thread cutting die and method of manufacturing same

Similar Documents

Publication Publication Date Title
Bagshaw et al. Current state of the art for renal replacement therapy in critically ill patients with acute kidney injury
Brophy et al. AN-69 membrane reactions are pH-dependent and preventable
Lemaire Strategies for blood management in orthopaedic and trauma surgery
Bayliss Dialysis in the poisoned patient
Rapeport et al. The use of “ketofol”(ketamine-propofol admixture) infusion in conjunction with regional anaesthesia
JP2006502231A5 (https=)
Chan et al. Hong Kong’s experience on the use of extracorporeal membrane oxygenation for the treatment of influenza A (H1N1)
Movilli et al. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy
JP2005511504A5 (https=)
Matsuda et al. Comparison of efficacy between continuous hemodiafiltration with a PMMA membrane hemofilter and a PAN membrane hemofilter in the treatment of a patient with septic acute renal failure
RU2005113240A (ru) Способ лечения пациентов с массивной потерей крови
US20070275086A1 (en) Use of Increased Molecular-Weight Hirudin as an Anticoagulant in Extracorporeal Kidney Replace Therapy
Huang et al. Delayed near-fatal anaphylactic reaction induced by the F10-HPS polysulphone haemodialyser
Li et al. The roller coaster of lamotrigine levels: Successful treatment of massive lamotrigine overdose with continuous veno-venous hemodiafiltration and rifampin
Buturović‐Ponikvar et al. Citrate anticoagulation during plasma exchange in a patient with thrombotic thrombocytopenic purpura: short heparin‐free hemodialysis helps to attenuate citrate load
JP2023500654A5 (https=)
Hothi et al. Pediatric hemodialysis prescription, complications, and future directions
Lu et al. Acute massive gentamicin intoxication in a patient with end-stage renal disease
Chaignon et al. Hemodynamic effects of hemodialysis and hemofiltration
Chan et al. Ammonia detoxification by continuous venovenous haemofiltration in an infant with urea cycle defect
Low et al. Relative efficacy of haemoperfusion, haemodialysis and CAPD in the removal of procainamide and NAPA in a patient with severe procainamide toxicity
Trakarnvanich et al. The efficacy of single-needle versus double-needle hemodialysis in chronic renal failure
Pierratos et al. Nocturnal hemodialysis: An update
RU2530759C1 (ru) Способ детоксикации организма
Lambie et al. Prospective study of gentamicin locking of tunnelled dialysis catheters: the effect on infection rates and CRP